Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Drug"" wg kryterium: Temat


Tytuł :
COVID-19: A Defining Moment for Clinical Pharmacology?
Autorzy :
van der Graaf PH; Certara, Canterbury, UK.; Leiden University, Leiden, The Netherlands.
Giacomini KM; University of California San Francisco, San Francisco, California, USA.
Pokaż więcej
Źródło :
Clinical pharmacology and therapeutics [Clin Pharmacol Ther] 2020 Jul; Vol. 108 (1), pp. 11-15.
Typ publikacji :
Editorial
Journal Info :
Publisher: Wiley Country of Publication: United States NLM ID: 0372741 Publication Model: Print Cited Medium: Internet ISSN: 1532-6535 (Electronic) Linking ISSN: 00099236 NLM ISO Abbreviation: Clin. Pharmacol. Ther. Subsets: Core Clinical (AIM); MEDLINE
MeSH Terms :
Coronavirus Infections*/drug therapy
Coronavirus Infections*/epidemiology
Pandemics*
Pharmacology, Clinical*/methods
Pharmacology, Clinical*/trends
Pneumonia, Viral*/drug therapy
Pneumonia, Viral*/epidemiology
Antiviral Agents/*pharmacology
Betacoronavirus/*drug effects
Drug Development/*organization & administration
Drug Discovery/methods ; Drug Discovery/trends ; Drug Repositioning/methods ; Drug Repositioning/trends ; Humans ; Pharmacovigilance ; Research
SCR Disease Name :
COVID-19
SCR Organism :
severe acute respiratory syndrome coronavirus 2
Opinia redakcyjna
Tytuł :
High Throughput Virtual Screening to Discover Inhibitors of the Main Protease of the Coronavirus SARS-CoV-2.
Autorzy :
Olubiyi OO; Institute of Biological Information Processing: Structural Biochemistry, Forschungszentrum Jülich, 52428 Jülich, Germany.; Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Obafemi Awolowo University, Ile-Ife 220005, Nigeria.
Olagunju M; Institute of Biological Information Processing: Structural Biochemistry, Forschungszentrum Jülich, 52428 Jülich, Germany.
Keutmann M; Institute of Biological Information Processing: Structural Biochemistry, Forschungszentrum Jülich, 52428 Jülich, Germany.
Loschwitz J; Institute of Biological Information Processing: Structural Biochemistry, Forschungszentrum Jülich, 52428 Jülich, Germany.; Institute of Theoretical and Computational Chemistry, Heinrich Heine University Düsseldorf, 40225 Düsseldorf, Germany.
Strodel B; Institute of Biological Information Processing: Structural Biochemistry, Forschungszentrum Jülich, 52428 Jülich, Germany.; Institute of Theoretical and Computational Chemistry, Heinrich Heine University Düsseldorf, 40225 Düsseldorf, Germany.
Pokaż więcej
Źródło :
Molecules (Basel, Switzerland) [Molecules] 2020 Jul 13; Vol. 25 (14). Date of Electronic Publication: 2020 Jul 13.
Typ publikacji :
Journal Article
Journal Info :
Publisher: MDPI Country of Publication: Switzerland NLM ID: 100964009 Publication Model: Electronic Cited Medium: Internet ISSN: 1420-3049 (Electronic) Linking ISSN: 14203049 NLM ISO Abbreviation: Molecules Subsets: MEDLINE
MeSH Terms :
Drug Discovery*
Betacoronavirus/*enzymology
Coronavirus Infections/*drug therapy
Pneumonia, Viral/*drug therapy
Protease Inhibitors/*pharmacology
Viral Nonstructural Proteins/*antagonists & inhibitors
Binding Sites ; Computer Simulation ; Cysteine Endopeptidases ; Drug Design ; Humans ; Inhibitory Concentration 50 ; Ligands ; Models, Molecular ; Molecular Structure ; Pandemics ; Software ; Thermodynamics
SCR Disease Name :
COVID-19
SCR Organism :
severe acute respiratory syndrome coronavirus 2
Czasopismo naukowe
Tytuł :
Hospital Pharmacy Compounding against COVID-19 pandemic.
Transliterated Title :
La farmacotecnia hospitalaria frente a la COVID-19.
Autorzy :
Alonso-Herreros JM; Servicio de Farmacia Hospitalaria, Hospital Los Arcos Mar Menor, Pozo Aledo, Murcia. España. .
Berisa-Prado S; Servicio de Farmacia Hospitalaria, Instituto Oftalmológico Fernández-Vega, Oviedo (Asturias). España. .
Cañete-Ramírez C; Servicio de Farmacia, Hospital Universitari Vall d'Hebron, Barcelona. España. .
Dávila-Pousa C; Servicio de Farmacia, Complexo Hospitalario Universitario, Pontevedra. España. .
Flox-Benítez MDP; Servicio de Farmacia, Hospital Universitario Santa Cristina, Madrid. España. .
Ladrón de Guevara-García M; Unidad de Gestión Clínica de Farmacia, Hospital Universitario Virgen del Rocío, Sevilla. España. .
López-Cabezas C; Servei de Farmàcia, Hospital Clínic, Barcelona. España. .
Martín de Rosales-Cabrera AM; Servicio de Farmacia, Hospital Universitario Fundación Alcorcón, Alcorcón (Madrid). España. .
Ramos-Martínez B; Servicio de Farmacia, Hospital Universitario de la Princesa, Madrid. España. .
Pokaż więcej
Źródło :
Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria [Farm Hosp] 2020 Jun 12; Vol. 44 (7), pp. 49-52. Date of Electronic Publication: 2020 Jun 12.
Typ publikacji :
Journal Article
Journal Info :
Publisher: Sociedad Española de Farmacia Hospitalaria Country of Publication: Spain NLM ID: 9440679 Publication Model: Electronic Cited Medium: Internet ISSN: 2171-8695 (Electronic) Linking ISSN: 11306343 NLM ISO Abbreviation: Farm Hosp Subsets: MEDLINE
MeSH Terms :
Betacoronavirus*
Drug Compounding*
Pandemics*
Coronavirus Infections/*drug therapy
Pharmacy Service, Hospital/*organization & administration
Pneumonia, Viral/*drug therapy
Administration, Oral ; Antiviral Agents/supply & distribution ; Antiviral Agents/therapeutic use ; Blood Component Transfusion ; Disinfection ; Drug Administration Routes ; Drug Interactions ; Drug Stability ; Equipment Contamination/prevention & control ; Excipients ; Forecasting ; Home Care Services ; Humans ; Hydroxychloroquine/administration & dosage ; Hydroxychloroquine/chemistry ; Infusions, Intravenous ; Lopinavir/administration & dosage ; Personal Protective Equipment/supply & distribution ; Platelet-Rich Plasma ; Ritonavir/administration & dosage ; Solutions
SCR Disease Name :
COVID-19
SCR Protocol :
COVID-19 drug treatment
SCR Organism :
severe acute respiratory syndrome coronavirus 2
Czasopismo naukowe
Tytuł :
COVID-19: CADD to the rescue.
Autorzy :
Onawole AT; Department of Chemistry, King Fahd University of Petroleum and Minerals, Dhahran, 31261 Saudi Arabia.
Sulaiman KO; Department of Chemistry, University of Saskatchewan, 110 Science Place, Saskatoon, Saskatchewan S7N 5C9, Canada. Electronic address: .
Kolapo TU; Department of Veterinary Parasitology and Entomology, University of Ilorin,P.M.B. 1515, Ilorin, Nigeria; Department of Veterinary Microbiology, University of Saskatchewan, 52 Campus Drive, Saskatoon, Saskatchewan S7N 5B4, Canada.
Akinde FO; School of Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, Liaoning, China.
Adegoke RO; Department of Pure and Applied Biology, Ladoke Akintola University of Technology, P.M.B. 4000, Ogbomoso, Nigeria.
Pokaż więcej
Źródło :
Virus research [Virus Res] 2020 Aug; Vol. 285, pp. 198022. Date of Electronic Publication: 2020 May 15.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
Journal Info :
Publisher: Elsevier Science Country of Publication: Netherlands NLM ID: 8410979 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1872-7492 (Electronic) Linking ISSN: 01681702 NLM ISO Abbreviation: Virus Res. Subsets: MEDLINE
MeSH Terms :
Drug Design*
Antiviral Agents/*chemistry
Antiviral Agents/*pharmacology
Betacoronavirus/*drug effects
Coronavirus Infections/*drug therapy
Pneumonia, Viral/*drug therapy
Spike Glycoprotein, Coronavirus/*antagonists & inhibitors
Antiviral Agents/metabolism ; Antiviral Agents/toxicity ; Betacoronavirus/physiology ; Drug Evaluation, Preclinical/methods ; Humans ; Ligands ; Machine Learning ; Models, Molecular ; Molecular Docking Simulation ; Pandemics ; Protein Binding ; Protein Structure, Tertiary ; Spike Glycoprotein, Coronavirus/chemistry ; Spike Glycoprotein, Coronavirus/metabolism ; Virus Internalization/drug effects
SCR Disease Name :
COVID-19
SCR Protocol :
COVID-19 drug treatment
SCR Organism :
severe acute respiratory syndrome coronavirus 2
Czasopismo naukowe
Tytuł :
Identification of potential inhibitors of three key enzymes of SARS-CoV2 using computational approach.
Autorzy :
Iftikhar H; Department of Biology, Syed Babar Ali School of Science and Engineering, Lahore University of Management Sciences, Lahore, Pakistan.
Ali HN; Department of Biology, Syed Babar Ali School of Science and Engineering, Lahore University of Management Sciences, Lahore, Pakistan.
Farooq S; Department of Computer Science, National University of Computer & Emerging Sciences, Islamabad, Pakistan.
Naveed H; Department of Computer Science, National University of Computer & Emerging Sciences, Islamabad, Pakistan. Electronic address: .
Shahzad-Ul-Hussan S; Department of Biology, Syed Babar Ali School of Science and Engineering, Lahore University of Management Sciences, Lahore, Pakistan. Electronic address: .
Pokaż więcej
Źródło :
Computers in biology and medicine [Comput Biol Med] 2020 Jul; Vol. 122, pp. 103848. Date of Electronic Publication: 2020 Jun 09.
Typ publikacji :
Journal Article
Journal Info :
Publisher: Elsevier Country of Publication: United States NLM ID: 1250250 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0534 (Electronic) Linking ISSN: 00104825 NLM ISO Abbreviation: Comput. Biol. Med. Subsets: MEDLINE
MeSH Terms :
Drug Repositioning*
Betacoronavirus/*enzymology
Coronavirus Infections/*drug therapy
Pneumonia, Viral/*drug therapy
Protease Inhibitors/*pharmacology
Catalytic Domain ; Computer Simulation ; Dimerization ; Drug Design ; Humans ; Molecular Docking Simulation ; Pandemics ; Protease Inhibitors/chemistry ; Quinoxalines/pharmacology ; Rimantadine/pharmacology ; Viral Proteins/chemistry
SCR Disease Name :
COVID-19
SCR Protocol :
COVID-19 drug treatment
SCR Organism :
severe acute respiratory syndrome coronavirus 2
Czasopismo naukowe
Tytuł :
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
Autorzy :
Gordon DE; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; J. David Gladstone Institutes, San Francisco, CA, USA.; Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, USA.
Jang GM; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; J. David Gladstone Institutes, San Francisco, CA, USA.; Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, USA.
Bouhaddou M; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; J. David Gladstone Institutes, San Francisco, CA, USA.; Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, USA.
Xu J; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; J. David Gladstone Institutes, San Francisco, CA, USA.; Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, USA.
Obernier K; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; J. David Gladstone Institutes, San Francisco, CA, USA.; Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, USA.
White KM; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.; Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
O'Meara MJ; Department of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, MI, USA.
Rezelj VV; Viral Populations and Pathogenesis Unit, CNRS UMR 3569, Institut Pasteur, Paris, France.
Guo JZ; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; J. David Gladstone Institutes, San Francisco, CA, USA.; Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, USA.
Swaney DL; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; J. David Gladstone Institutes, San Francisco, CA, USA.; Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, USA.
Tummino TA; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; Department of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA, USA.
Hüttenhain R; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; J. David Gladstone Institutes, San Francisco, CA, USA.; Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, USA.
Kaake RM; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; J. David Gladstone Institutes, San Francisco, CA, USA.; Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, USA.
Richards AL; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; J. David Gladstone Institutes, San Francisco, CA, USA.; Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, USA.
Tutuncuoglu B; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; J. David Gladstone Institutes, San Francisco, CA, USA.; Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, USA.
Foussard H; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; J. David Gladstone Institutes, San Francisco, CA, USA.; Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, USA.
Batra J; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; J. David Gladstone Institutes, San Francisco, CA, USA.; Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, USA.
Haas K; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; J. David Gladstone Institutes, San Francisco, CA, USA.; Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, USA.
Modak M; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; J. David Gladstone Institutes, San Francisco, CA, USA.; Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, USA.
Kim M; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; J. David Gladstone Institutes, San Francisco, CA, USA.; Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, USA.
Haas P; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; J. David Gladstone Institutes, San Francisco, CA, USA.; Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, USA.
Polacco BJ; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; J. David Gladstone Institutes, San Francisco, CA, USA.; Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, USA.
Braberg H; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; J. David Gladstone Institutes, San Francisco, CA, USA.; Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, USA.
Fabius JM; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; J. David Gladstone Institutes, San Francisco, CA, USA.; Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, USA.
Eckhardt M; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; J. David Gladstone Institutes, San Francisco, CA, USA.; Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, USA.
Soucheray M; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; J. David Gladstone Institutes, San Francisco, CA, USA.; Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, USA.
Bennett MJ; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; J. David Gladstone Institutes, San Francisco, CA, USA.; Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, USA.
Cakir M; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; J. David Gladstone Institutes, San Francisco, CA, USA.; Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, USA.
McGregor MJ; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; J. David Gladstone Institutes, San Francisco, CA, USA.; Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, USA.
Li Q; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; J. David Gladstone Institutes, San Francisco, CA, USA.; Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, USA.
Meyer B; Viral Populations and Pathogenesis Unit, CNRS UMR 3569, Institut Pasteur, Paris, France.
Roesch F; Viral Populations and Pathogenesis Unit, CNRS UMR 3569, Institut Pasteur, Paris, France.
Vallet T; Viral Populations and Pathogenesis Unit, CNRS UMR 3569, Institut Pasteur, Paris, France.
Mac Kain A; Viral Populations and Pathogenesis Unit, CNRS UMR 3569, Institut Pasteur, Paris, France.
Miorin L; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.; Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Moreno E; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.; Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Naing ZZC; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; J. David Gladstone Institutes, San Francisco, CA, USA.; Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, USA.
Zhou Y; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; J. David Gladstone Institutes, San Francisco, CA, USA.; Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, USA.
Peng S; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; Department of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA, USA.
Shi Y; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, USA.; Howard Hughes Medical Institute, University of California San Francisco, San Francisco, CA, USA.
Zhang Z; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, USA.; Howard Hughes Medical Institute, University of California San Francisco, San Francisco, CA, USA.
Shen W; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, USA.; Howard Hughes Medical Institute, University of California San Francisco, San Francisco, CA, USA.
Kirby IT; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, USA.; Howard Hughes Medical Institute, University of California San Francisco, San Francisco, CA, USA.
Melnyk JE; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, USA.; Howard Hughes Medical Institute, University of California San Francisco, San Francisco, CA, USA.
Chorba JS; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, USA.; Howard Hughes Medical Institute, University of California San Francisco, San Francisco, CA, USA.
Lou K; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, USA.; Howard Hughes Medical Institute, University of California San Francisco, San Francisco, CA, USA.
Dai SA; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, USA.; Howard Hughes Medical Institute, University of California San Francisco, San Francisco, CA, USA.
Barrio-Hernandez I; European Molecular Biology Laboratory (EMBL), European Bioinformatics Institute, Wellcome Genome Campus, Cambridge, UK.
Memon D; European Molecular Biology Laboratory (EMBL), European Bioinformatics Institute, Wellcome Genome Campus, Cambridge, UK.
Hernandez-Armenta C; European Molecular Biology Laboratory (EMBL), European Bioinformatics Institute, Wellcome Genome Campus, Cambridge, UK.
Lyu J; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; Department of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA, USA.
Mathy CJP; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, CA, USA.; The UC Berkeley-UCSF Graduate Program in Bioengineering, University of California San Francisco, San Francisco, CA, USA.
Perica T; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, CA, USA.
Pilla KB; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, CA, USA.
Ganesan SJ; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, CA, USA.
Saltzberg DJ; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, CA, USA.
Rakesh R; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, CA, USA.
Liu X; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; Department of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA, USA.
Rosenthal SB; Center for Computational Biology and Bioinformatics, Department of Medicine, University of California San Diego, San Diego, CA, USA.
Calviello L; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Department of Cell and Tissue Biology, University of California San Francisco, San Francisco, CA, USA.
Venkataramanan S; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Department of Cell and Tissue Biology, University of California San Francisco, San Francisco, CA, USA.
Liboy-Lugo J; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Department of Cell and Tissue Biology, University of California San Francisco, San Francisco, CA, USA.
Lin Y; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Department of Cell and Tissue Biology, University of California San Francisco, San Francisco, CA, USA.
Huang XP; Department of Pharmacology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, USA.
Liu Y; Department of Pharmacology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, USA.
Wankowicz SA; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, CA, USA.; Biophysics Graduate Program, University of California San Francisco, San Francisco, CA, USA.
Bohn M; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; Department of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA, USA.
Safari M; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; Department of Biochemistry and Biophysics, University of California San Francisco, San Francisco, CA, USA.
Ugur FS; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, USA.; Department of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA, USA.
Koh C; Viral Populations and Pathogenesis Unit, CNRS UMR 3569, Institut Pasteur, Paris, France.
Savar NS; Viral Populations and Pathogenesis Unit, CNRS UMR 3569, Institut Pasteur, Paris, France.
Tran QD; Viral Populations and Pathogenesis Unit, CNRS UMR 3569, Institut Pasteur, Paris, France.
Shengjuler D; Viral Populations and Pathogenesis Unit, CNRS UMR 3569, Institut Pasteur, Paris, France.
Fletcher SJ; Viral Populations and Pathogenesis Unit, CNRS UMR 3569, Institut Pasteur, Paris, France.
O'Neal MC; Zoic Labs, Culver City, CA, USA.
Cai Y; Zoic Labs, Culver City, CA, USA.
Chang JCJ; Zoic Labs, Culver City, CA, USA.
Broadhurst DJ; Zoic Labs, Culver City, CA, USA.
Klippsten S; Zoic Labs, Culver City, CA, USA.
Sharp PP; Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, USA.
Wenzell NA; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, USA.
Kuzuoglu-Ozturk D; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.; Department of Urology, University of California San Francisco, San Francisco, CA, USA.
Wang HY; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, USA.
Trenker R; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; Cardiovascular Research Institute, University of California San Francisco, San Francisco, CA, USA.
Young JM; Division of Basic Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Cavero DA; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; J. David Gladstone Institutes, San Francisco, CA, USA.; George William Hooper Foundation, Department of Microbiology and Immunology, University of California San Francisco, San Francisco, CA, USA.
Hiatt J; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; J. David Gladstone Institutes, San Francisco, CA, USA.; Medical Scientist Training Program, University of California San Francisco, San Francisco, CA, USA.
Roth TL; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; J. David Gladstone Institutes, San Francisco, CA, USA.; George William Hooper Foundation, Department of Microbiology and Immunology, University of California San Francisco, San Francisco, CA, USA.; Medical Scientist Training Program, University of California San Francisco, San Francisco, CA, USA.
Rathore U; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; J. David Gladstone Institutes, San Francisco, CA, USA.; George William Hooper Foundation, Department of Microbiology and Immunology, University of California San Francisco, San Francisco, CA, USA.
Subramanian A; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; George William Hooper Foundation, Department of Microbiology and Immunology, University of California San Francisco, San Francisco, CA, USA.
Noack J; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; George William Hooper Foundation, Department of Microbiology and Immunology, University of California San Francisco, San Francisco, CA, USA.
Hubert M; Virus and Immunity Unit, Institut Pasteur, Paris, France.
Stroud RM; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; Department of Biochemistry and Biophysics, University of California San Francisco, San Francisco, CA, USA.
Frankel AD; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; Department of Biochemistry and Biophysics, University of California San Francisco, San Francisco, CA, USA.
Rosenberg OS; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; Department of Biochemistry and Biophysics, University of California San Francisco, San Francisco, CA, USA.; Department of Medicine, University of California San Francisco, San Francisco, CA, USA.
Verba KA; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; Department of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA, USA.
Agard DA; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; Department of Biochemistry and Biophysics, University of California San Francisco, San Francisco, CA, USA.
Ott M; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; J. David Gladstone Institutes, San Francisco, CA, USA.; Department of Medicine, University of California San Francisco, San Francisco, CA, USA.
Emerman M; Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Jura N; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, USA.; Cardiovascular Research Institute, University of California San Francisco, San Francisco, CA, USA.
von Zastrow M; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, USA.; Department of Psychiatry, University of California San Francisco, San Francisco, CA, USA.
Verdin E; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Department of Medicine, University of California San Francisco, San Francisco, CA, USA.; Buck Institute for Research on Aging, Novato, CA, USA.
Ashworth A; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.
Schwartz O; Virus and Immunity Unit, Institut Pasteur, Paris, France.
d'Enfert C; Direction Scientifique, Institut Pasteur, Paris, France.
Mukherjee S; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; George William Hooper Foundation, Department of Microbiology and Immunology, University of California San Francisco, San Francisco, CA, USA.
Jacobson M; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; Department of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA, USA.
Malik HS; Division of Basic Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Fujimori DG; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, USA.; Department of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA, USA.
Ideker T; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Division of Genetics, Department of Medicine, University of California San Diego, San Diego, CA, USA.
Craik CS; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; Department of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA, USA.; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.
Floor SN; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Department of Cell and Tissue Biology, University of California San Francisco, San Francisco, CA, USA.; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.
Fraser JS; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, CA, USA.
Gross JD; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; Department of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA, USA.
Sali A; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; Department of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA, USA.; Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, CA, USA.
Roth BL; Department of Pharmacology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, USA.
Ruggero D; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, USA.; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.; Department of Urology, University of California San Francisco, San Francisco, CA, USA.
Taunton J; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, USA.
Kortemme T; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.; Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, CA, USA.; The UC Berkeley-UCSF Graduate Program in Bioengineering, University of California San Francisco, San Francisco, CA, USA.
Beltrao P; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; European Molecular Biology Laboratory (EMBL), European Bioinformatics Institute, Wellcome Genome Campus, Cambridge, UK.
Vignuzzi M; Viral Populations and Pathogenesis Unit, CNRS UMR 3569, Institut Pasteur, Paris, France. .
García-Sastre A; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. .; Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. .; Department of Medicine, Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai, New York, NY, USA. .; The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. .
Shokat KM; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA. .; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA. .; Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, USA. .; Howard Hughes Medical Institute, University of California San Francisco, San Francisco, CA, USA. .
Shoichet BK; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA. .; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA. .; Department of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA, USA. .
Krogan NJ; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA. .; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA. .; J. David Gladstone Institutes, San Francisco, CA, USA. .; Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, USA. .; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. .
Pokaż więcej
Źródło :
Nature [Nature] 2020 Jul; Vol. 583 (7816), pp. 459-468. Date of Electronic Publication: 2020 Apr 30.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
Journal Info :
Publisher: Nature Publishing Group Country of Publication: England NLM ID: 0410462 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-4687 (Electronic) Linking ISSN: 00280836 NLM ISO Abbreviation: Nature Subsets: MEDLINE
MeSH Terms :
Drug Repositioning*
Molecular Targeted Therapy*
Protein Interaction Maps*
Betacoronavirus/*drug effects
Coronavirus Infections/*drug therapy
Coronavirus Infections/*metabolism
Pneumonia, Viral/*drug therapy
Pneumonia, Viral/*metabolism
Viral Proteins/*metabolism
Animals ; Antiviral Agents/classification ; Antiviral Agents/pharmacology ; Betacoronavirus/genetics ; Betacoronavirus/metabolism ; Betacoronavirus/pathogenicity ; Chlorocebus aethiops ; Cloning, Molecular ; Coronavirus Infections/immunology ; Coronavirus Infections/virology ; Drug Evaluation, Preclinical ; HEK293 Cells ; Host-Pathogen Interactions/drug effects ; Humans ; Immunity, Innate ; Mass Spectrometry ; Pandemics ; Pneumonia, Viral/immunology ; Pneumonia, Viral/virology ; Protein Binding ; Protein Biosynthesis/drug effects ; Protein Domains ; Protein Interaction Mapping ; Receptors, sigma/metabolism ; SKP Cullin F-Box Protein Ligases/metabolism ; Vero Cells ; Viral Proteins/genetics
SCR Disease Name :
COVID-19
SCR Protocol :
COVID-19 drug treatment
SCR Organism :
severe acute respiratory syndrome coronavirus 2
Czasopismo naukowe
Tytuł :
Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs.
Autorzy :
Jeon S; Zoonotic Virus Laboratory, Institut Pasteur Korea, Seongnam, South Korea.
Ko M; Zoonotic Virus Laboratory, Institut Pasteur Korea, Seongnam, South Korea.
Lee J; Zoonotic Virus Laboratory, Institut Pasteur Korea, Seongnam, South Korea.
Choi I; Medicinal Chemistry, Institut Pasteur Korea, Seongnam, South Korea.
Byun SY; Screening Discovery Platform, Institut Pasteur Korea, Seongnam, South Korea.
Park S; Screening Discovery Platform, Institut Pasteur Korea, Seongnam, South Korea.
Shum D; Screening Discovery Platform, Institut Pasteur Korea, Seongnam, South Korea.
Kim S; Zoonotic Virus Laboratory, Institut Pasteur Korea, Seongnam, South Korea .
Pokaż więcej
Źródło :
Antimicrobial agents and chemotherapy [Antimicrob Agents Chemother] 2020 Jun 23; Vol. 64 (7). Date of Electronic Publication: 2020 Jun 23 (Print Publication: 2020).
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
Journal Info :
Publisher: American Society for Microbiology Country of Publication: United States NLM ID: 0315061 Publication Model: Electronic-Print Cited Medium: Internet ISSN: 1098-6596 (Electronic) Linking ISSN: 00664804 NLM ISO Abbreviation: Antimicrob. Agents Chemother. Subsets: MEDLINE
MeSH Terms :
Drug Repositioning*
Betacoronavirus/*drug effects
Coronavirus Infections/*drug therapy
Niclosamide/*pharmacology
Pneumonia, Viral/*drug therapy
Pregnenediones/*pharmacology
Animals ; Anti-Inflammatory Agents/pharmacology ; Antiviral Agents/pharmacology ; Cell Line ; Chlorocebus aethiops ; Drug Evaluation, Preclinical/methods ; Humans ; Pandemics ; Vero Cells
SCR Disease Name :
COVID-19
SCR Organism :
severe acute respiratory syndrome coronavirus 2
Czasopismo naukowe
Tytuł :
Drug Evaluation during the Covid-19 Pandemic.
Autorzy :
Rome BN; From the Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston.
Avorn J; From the Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston.
Pokaż więcej
Źródło :
The New England journal of medicine [N Engl J Med] 2020 Jun 11; Vol. 382 (24), pp. 2282-2284. Date of Electronic Publication: 2020 Apr 14.
Typ publikacji :
Journal Article
Journal Info :
Publisher: Massachusetts Medical Society Country of Publication: United States NLM ID: 0255562 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1533-4406 (Electronic) Linking ISSN: 00284793 NLM ISO Abbreviation: N. Engl. J. Med. Subsets: Core Clinical (AIM); MEDLINE
MeSH Terms :
Drug Approval*
Coronavirus Infections/*drug therapy
Drug Evaluation/*standards
Pneumonia, Viral/*drug therapy
Betacoronavirus ; Chloroquine/supply & distribution ; Chloroquine/therapeutic use ; Clinical Trials as Topic ; Drugs, Investigational/therapeutic use ; Humans ; Hydroxychloroquine/supply & distribution ; Hydroxychloroquine/therapeutic use ; Off-Label Use ; Pandemics ; United States ; United States Food and Drug Administration
SCR Disease Name :
COVID-19
SCR Protocol :
COVID-19 drug treatment
SCR Organism :
severe acute respiratory syndrome coronavirus 2
Czasopismo naukowe
Tytuł :
Drug Development and Medicinal Chemistry Efforts toward SARS-Coronavirus and Covid-19 Therapeutics.
Autorzy :
Ghosh AK; Department of Chemistry, Purdue University, West Lafayette, IN 47907, USA.; Department of Medicinal Chemistry and Molecular Pharmacolgy, Purdue University, West Lafayette, IN 47907, USA.
Brindisi M; Department of Chemistry, Purdue University, West Lafayette, IN 47907, USA.; Department of Excellence of Pharmacy, University of Naples Federico II, 80131, Naples, Italy.
Shahabi D; Department of Chemistry, Purdue University, West Lafayette, IN 47907, USA.
Chapman ME; Department of Biochemistry, Purdue University, West Lafayette, IN 47907, USA.
Mesecar AD; Department of Chemistry, Purdue University, West Lafayette, IN 47907, USA.; Department of Biochemistry, Purdue University, West Lafayette, IN 47907, USA.; Department of Biological Sciences, Purdue University, West Lafayette, IN 47907, USA.
Pokaż więcej
Źródło :
ChemMedChem [ChemMedChem] 2020 Jun 04; Vol. 15 (11), pp. 907-932. Date of Electronic Publication: 2020 May 07.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
Journal Info :
Publisher: Wiley-VCH Country of Publication: Germany NLM ID: 101259013 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1860-7187 (Electronic) Linking ISSN: 18607179 NLM ISO Abbreviation: ChemMedChem Subsets: MEDLINE
MeSH Terms :
Drug Development*
Antiviral Agents/*therapeutic use
Chemistry, Pharmaceutical/*trends
Coronavirus Infections/*drug therapy
Pneumonia, Viral/*drug therapy
Antiviral Agents/pharmacology ; Drug Discovery ; Humans ; Models, Molecular ; Pandemics ; Protease Inhibitors/therapeutic use
SCR Disease Name :
COVID-19
Czasopismo naukowe
Tytuł :
Heparin resistance in COVID-19 patients in the intensive care unit.
Autorzy :
White D; Department of Haematology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
MacDonald S; Department of Haematology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Bull T; Department of Haematology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Hayman M; Department of Haematology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
de Monteverde-Robb R; Pharmacy Department, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Sapsford D; Pharmacy Department, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Lavinio A; Department of Intensive Care Medicine, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Varley J; Department of Intensive Care Medicine, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Johnston A; Department of Intensive Care Medicine, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Besser M; Department of Haematology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Thomas W; Department of Haematology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK. .
Pokaż więcej
Źródło :
Journal of thrombosis and thrombolysis [J Thromb Thrombolysis] 2020 Aug; Vol. 50 (2), pp. 287-291.
Typ publikacji :
Journal Article
Journal Info :
Publisher: Kluwer Academic Publishers Country of Publication: Netherlands NLM ID: 9502018 Publication Model: Print Cited Medium: Internet ISSN: 1573-742X (Electronic) Linking ISSN: 09295305 NLM ISO Abbreviation: J. Thromb. Thrombolysis Subsets: MEDLINE
MeSH Terms :
Drug Resistance*
Intensive Care Units*
Anticoagulants/*therapeutic use
Betacoronavirus/*pathogenicity
Blood Coagulation/*drug effects
Coronavirus Infections/*therapy
Heparin/*therapeutic use
Pneumonia, Viral/*therapy
Thrombosis/*drug therapy
Adult ; Aged ; Anticoagulants/adverse effects ; Blood Coagulation Tests ; Coronavirus Infections/blood ; Coronavirus Infections/diagnosis ; Coronavirus Infections/virology ; Drug Monitoring ; Female ; Heparin/adverse effects ; Host-Pathogen Interactions ; Humans ; Male ; Middle Aged ; Pandemics ; Pneumonia, Viral/blood ; Pneumonia, Viral/diagnosis ; Pneumonia, Viral/virology ; Retrospective Studies ; Thrombosis/blood ; Thrombosis/diagnosis ; Thrombosis/virology ; Treatment Outcome
SCR Disease Name :
COVID-19
SCR Organism :
severe acute respiratory syndrome coronavirus 2
Czasopismo naukowe
Tytuł :
Pharmacologic Treatment of Transplant Recipients Infected With SARS-CoV-2: Considerations Regarding Therapeutic Drug Monitoring and Drug-Drug Interactions.
Autorzy :
Elens L; Louvain Drug Research Institute (LDRI), Integrated Pharmacometrics, Pharmacogenomics and Pharmacokinetics (PMGK), Université catholique de Louvain (UCLouvain), Brussels, Belgium.; Institut de Recherche Expérimentale et Clinique (IREC), Louvain Center for Toxicology and Applied Pharmacology (LTAP), Université catholique de Louvain (UCLouvain), Brussels, Belgium.
Langman LJ; Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, Minnesota.
Hesselink DA; Division of Nephrology and Transplantation, Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands.; Rotterdam Transplant Group.
Bergan S; Department of Pharmacology, Oslo University Hospital, Oslo, Norway.
Moes DJAR; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, the Netherlands.
Molinaro M; Clinical and Experimental Pharmacokinetics Lab, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
Venkataramanan R; School of Pharmacy and Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania.
Lemaitre F; Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en sante[Combining Acute Accent], environnement et travail)-UMR_S 1085, Rennes, France.; INSERM, Centre d'Investigation Clinique, CIC 1414, Rennes, France.
Pokaż więcej
Źródło :
Therapeutic drug monitoring [Ther Drug Monit] 2020 Jun; Vol. 42 (3), pp. 360-368.
Typ publikacji :
Journal Article; Review
Journal Info :
Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 7909660 Publication Model: Print Cited Medium: Internet ISSN: 1536-3694 (Electronic) Linking ISSN: 01634356 NLM ISO Abbreviation: Ther Drug Monit Subsets: MEDLINE
MeSH Terms :
Drug Monitoring*
Transplant Recipients*
Antiviral Agents/*adverse effects
Coronavirus Infections/*drug therapy
Immunosuppressive Agents/*adverse effects
Pneumonia, Viral/*drug therapy
Adenosine Monophosphate/analogs & derivatives ; Alanine/analogs & derivatives ; Antibodies, Monoclonal, Humanized ; Antiviral Agents/therapeutic use ; Betacoronavirus ; Drug Interactions ; Glucocorticoids ; Humans ; Hydroxychloroquine ; Immunosuppressive Agents/therapeutic use ; Pandemics ; Protease Inhibitors
SCR Disease Name :
COVID-19
SCR Organism :
severe acute respiratory syndrome coronavirus 2
Czasopismo naukowe
Tytuł :
Primary chemoablation of low-grade upper tract urothelial carcinoma using UGN-101, a mitomycin-containing reverse thermal gel (OLYMPUS): an open-label, single-arm, phase 3 trial.
Autorzy :
Kleinmann N; Department of Urology, Sheba Medical Center, Ramat Gan, Israel.
Matin SF; Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Pierorazio PM; Brady Urological Institute, Johns Hopkins University, Baltimore, MD, USA.
Gore JL; Department of Urology, University of Washington Medical Center, Seattle, WA, USA.
Shabsigh A; Department of Urology, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
Hu B; Department of Urology, Loma Linda University, Loma Linda, CA, USA.
Chamie K; Department of Urology, University of California Los Angeles, Los Angeles, CA, USA.
Godoy G; Department of Urology, Baylor College of Medicine, Houston, TX, USA.
Hubosky S; Department of Urology, Sidney Kimmel Medical College at Thomas Jefferson University Hospitals, Philadelphia, PA, USA.
Rivera M; Department of Urology, Mayo Clinic Health System, Rochester, MN, USA.
O'Donnell M; Department of Urology, University of Iowa, Iowa City, IA, USA.
Quek M; Department of Urology, Loyola University Medical Center, Maywood, IL, USA.
Raman JD; Division of Urology, Penn State Health Milton S Hershey Medical Center, Hershey, PA, USA.
Knoedler JJ; Division of Urology, Penn State Health Milton S Hershey Medical Center, Hershey, PA, USA.
Scherr D; Department of Urology, Weill Medical College of Cornell University, New York, NY, USA.
Stern J; Department of Urology, Albert Einstein College of Medicine, Bronx, NY, USA.
Weight C; Department of Urology, University of Minnesota Health, Minneapolis, MN, USA.
Weizer A; Department of Urology, University of Michigan, Ann Arbor, MI, USA.
Woods M; Department of Urology, Loyola University Medical Center, Maywood, IL, USA.
Kaimakliotis H; Department of Urology, Indiana University School of Medicine, Indianapolis, IN, USA.
Smith AB; Department of Urology, University of North Carolina School of Medicine, Chapel Hill, NC, USA.
Linehan J; Department of Urology, John Wayne Cancer Institute, Santa Monica, CA, USA.
Coleman J; Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Humphreys MR; Department of Urology, Mayo Clinic Phoenix, Scottsdale, AZ, USA.
Pak R; Department of Urology, Mayo Clinic Jacksonville, Jacksonville, FL, USA.
Lifshitz D; Department of Urology, Rabin Medical Center, Tel Aviv, Israel.
Verni M; Urology Center of Las Vegas, Las Vegas, NV, USA.
Adibi M; Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Amin MB; Department of Pathology, University of Tennessee Health Science Center, Memphis, TN, USA.
Seltzer E; UroGen Pharma, New York, NY, USA.
Klein I; UroGen Pharma, Ra'anana, Israel.
Konorty M; UroGen Pharma, Ra'anana, Israel.
Strauss-Ayali D; UroGen Pharma, Ra'anana, Israel.
Hakim G; UroGen Pharma, Ra'anana, Israel.
Schoenberg M; Department of Urology, Albert Einstein College of Medicine, Bronx, NY, USA; UroGen Pharma, New York, NY, USA.
Lerner SP; Department of Urology, Baylor College of Medicine, Houston, TX, USA. Electronic address: .
Pokaż więcej
Źródło :
The Lancet. Oncology [Lancet Oncol] 2020 Jun; Vol. 21 (6), pp. 776-785. Date of Electronic Publication: 2020 Apr 29.
Typ publikacji :
Clinical Trial, Phase III; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
Journal Info :
Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 100957246 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-5488 (Electronic) Linking ISSN: 14702045 NLM ISO Abbreviation: Lancet Oncol. Subsets: MEDLINE
MeSH Terms :
Drug Carriers*
Antibiotics, Antineoplastic/*administration & dosage
Carcinoma/*drug therapy
Kidney Neoplasms/*drug therapy
Mitomycin/*administration & dosage
Urothelium/*drug effects
Adult ; Aged ; Aged, 80 and over ; Antibiotics, Antineoplastic/adverse effects ; Carcinoma/pathology ; Drug Compounding ; Female ; Humans ; Hydrogels ; Israel ; Kidney Neoplasms/pathology ; Male ; Middle Aged ; Mitomycin/adverse effects ; Neoplasm Grading ; Time Factors ; Treatment Outcome ; United States ; Urothelium/pathology
Czasopismo naukowe
Tytuł :
Chitosan capped pH-responsive hollow mesoporous silica nanoparticles for targeted chemo-photo combination therapy.
Autorzy :
Yan T; Key Laboratory of Animal Cellular and Genetic Engineering of Heilongjiang Province, College of Life Science, Northeast Agricultural University, Harbin, Heilongjiang, 150030, China.
He J; MIIT Key Laboratory of Critical Materials Technology for New Energy Conversion and Storage, School of Chemistry and Chemical Engineering, Harbin Institute of Technology, Harbin, Heilongjiang, 150001, China.
Liu R; Key Laboratory of Animal Cellular and Genetic Engineering of Heilongjiang Province, College of Life Science, Northeast Agricultural University, Harbin, Heilongjiang, 150030, China.
Liu Z; Key Laboratory of Animal Cellular and Genetic Engineering of Heilongjiang Province, College of Life Science, Northeast Agricultural University, Harbin, Heilongjiang, 150030, China.
Cheng J; Food Science College, Northeast Agricultural University, Harbin, Heilongjiang, 150030, China; Key Laboratory of Dairy Science (KLDS), Ministry of Education, Northeast Agricultural University, Harbin, Heilongjiang, 150030, China. Electronic address: .
Pokaż więcej
Źródło :
Carbohydrate polymers [Carbohydr Polym] 2020 Mar 01; Vol. 231, pp. 115706. Date of Electronic Publication: 2019 Dec 05.
Typ publikacji :
Journal Article
Journal Info :
Publisher: Elsevier Applied Science Publishers Country of Publication: England NLM ID: 8307156 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-1344 (Electronic) Linking ISSN: 01448617 NLM ISO Abbreviation: Carbohydr Polym Subsets: MEDLINE
MeSH Terms :
Drug Delivery Systems*
Drug Liberation*
Chitosan/*pharmacology
Neoplasms/*drug therapy
Antineoplastic Agents/chemistry ; Antineoplastic Agents/pharmacology ; Chitosan/chemistry ; Chlorophyll/analogs & derivatives ; Chlorophyll/chemistry ; Chlorophyll/pharmacology ; Combined Modality Therapy ; Doxorubicin/chemistry ; Doxorubicin/pharmacology ; Drug Resistance, Multiple/drug effects ; Endocytosis/drug effects ; Humans ; Hydrogen-Ion Concentration ; Metal Nanoparticles/chemistry ; Metal Nanoparticles/therapeutic use ; Silicon Dioxide/chemistry
Czasopismo naukowe
Tytuł :
FDA Initiative for Drug Facts Label for Over-the-Counter Naloxone.
Autorzy :
Cohen BR; From the Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD.
Mahoney KM; From the Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD.
Baro E; From the Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD.
Squire C; From the Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD.
Beck M; From the Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD.
Travis S; From the Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD.
Pike-McCrudden A; From the Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD.
Izem R; From the Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD.
Woodcock J; From the Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD.
Pokaż więcej
Źródło :
The New England journal of medicine [N Engl J Med] 2020 May 28; Vol. 382 (22), pp. 2129-2136.
Typ publikacji :
Journal Article
Journal Info :
Publisher: Massachusetts Medical Society Country of Publication: United States NLM ID: 0255562 Publication Model: Print Cited Medium: Internet ISSN: 1533-4406 (Electronic) Linking ISSN: 00284793 NLM ISO Abbreviation: N. Engl. J. Med. Subsets: Core Clinical (AIM); MEDLINE
MeSH Terms :
Comprehension*
Drug Labeling*/legislation & jurisprudence
Analgesics, Opioid/*poisoning
Drug Overdose/*drug therapy
Naloxone/*therapeutic use
Narcotic Antagonists/*therapeutic use
Nonprescription Drugs/*therapeutic use
Adolescent ; Adult ; Drug Overdose/therapy ; Government Regulation ; Humans ; Interviews as Topic ; United States ; United States Food and Drug Administration
Czasopismo naukowe
Tytuł :
ROS-Responsive Chitosan Coated Magnetic Iron Oxide Nanoparticles as Potential Vehicles for Targeted Drug Delivery in Cancer Therapy.
Autorzy :
Ayyanaar S; PG and Research Department of Chemistry, Chikkanna Government Arts College, Tiruppur 641 602, Tamilnadu, India.
Balachandran C; Faculty of Pharmaceutical Sciences, Tokyo University of Science, Noda 278-8510, Japan.
Bhaskar RC; Department of Chemistry, School of Advanced Sciences, Vellore Institute of Technology, Vellore 632014, Tamil Nadu, India.
Kesavan MP; Department of Chemistry, Hajee Karutha Rowther Howdia College, Uthamapalayam 625 533, Tamil Nadu, India.
Aoki S; Faculty of Pharmaceutical Sciences, Tokyo University of Science, Noda 278-8510, Japan.; Research Institute of Science and Technology, Tokyo University of Science, Noda 278-8510, Japan.
Raja RP; Centre for Biotechnology, Anna University, Chennai 600 025, Tamil Nadu, India.
Rajesh J; Chemistry Research Centre, Mohamed Sathak Engineering College, Kilakarai 623 806, Tamil Nadu, India.
Webster TJ; Department of Chemical Engineering, Northeastern University, Boston, MA 02115, USA.
Rajagopal G; PG and Research Department of Chemistry, Chikkanna Government Arts College, Tiruppur 641 602, Tamilnadu, India.
Pokaż więcej
Źródło :
International journal of nanomedicine [Int J Nanomedicine] 2020 May 12; Vol. 15, pp. 3333-3346. Date of Electronic Publication: 2020 May 12 (Print Publication: 2020).
Typ publikacji :
Journal Article
Journal Info :
Publisher: DOVE Medical Press Country of Publication: New Zealand NLM ID: 101263847 Publication Model: eCollection Cited Medium: Internet ISSN: 1178-2013 (Electronic) Linking ISSN: 11769114 NLM ISO Abbreviation: Int J Nanomedicine Subsets: MEDLINE
MeSH Terms :
Drug Delivery Systems*
Chitosan/*chemistry
Ferric Compounds/*chemistry
Magnetite Nanoparticles/*chemistry
Neoplasms/*drug therapy
Reactive Oxygen Species/*metabolism
Antineoplastic Agents/pharmacology ; Antineoplastic Agents/therapeutic use ; Cell Death/drug effects ; Cell Line, Tumor ; Drug Carriers/chemistry ; Drug Liberation ; Fluorouracil/pharmacology ; Fluorouracil/therapeutic use ; Humans ; Hydrogen-Ion Concentration ; Inhibitory Concentration 50 ; Magnetite Nanoparticles/ultrastructure ; Neoplasms/pathology ; Oleic Acid/chemistry ; Particle Size ; Spectroscopy, Fourier Transform Infrared ; Temperature ; X-Ray Diffraction
Czasopismo naukowe
Tytuł :
[Drug interaction monitoring of lopinavir/ritonavir in COVID-19 patients with cancer].
Autorzy :
Zheng XW; Department of Pharmacy, Cancer Hospital of University of Chinese Academy of Sciences, Institute of Cancer Research and Basic Medical Sciences of Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou 310022, China.
Tao G; Department of Oncology, Zhejiang Medical and Health Centre Hangzhou Hospital, Hangzhou 310022, China.
Zhang YW; Department of Pharmacy, Zhejiang Provincial People's Hospital(People's Hospital of Hangzhou Medical College), Hangzhou 310010, China.
Yang GN; Department of Pharmacy, Cancer Hospital of University of Chinese Academy of Sciences, Institute of Cancer Research and Basic Medical Sciences of Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou 310022, China.
Huang P; Department of Pharmacy, Zhejiang Provincial People's Hospital(People's Hospital of Hangzhou Medical College), Hangzhou 310010, China.
Pokaż więcej
Źródło :
Zhonghua nei ke za zhi [Zhonghua Nei Ke Za Zhi] 2020 May 01; Vol. 59 (5), pp. 400-404.
Typ publikacji :
Journal Article
Journal Info :
Publisher: Zhonghua yi xue hui Country of Publication: China NLM ID: 16210490R Publication Model: Print Cited Medium: Print ISSN: 0578-1426 (Print) Linking ISSN: 05781426 NLM ISO Abbreviation: Zhonghua Nei Ke Za Zhi Subsets: MEDLINE
MeSH Terms :
Drug Interactions*
Coronavirus Infections/*drug therapy
Lopinavir/*adverse effects
Neoplasms/*drug therapy
Pneumonia, Viral/*drug therapy
Ritonavir/*adverse effects
Betacoronavirus ; Drug Combinations ; Drug Monitoring ; Humans ; Pandemics
SCR Disease Name :
COVID-19
SCR Protocol :
COVID-19 drug treatment
SCR Organism :
severe acute respiratory syndrome coronavirus 2
Czasopismo naukowe
Tytuł :
Repurposing Antiviral Protease Inhibitors Using Extracellular Vesicles for Potential Therapy of COVID-19.
Autorzy :
Kumar S; Department of Pharmaceutical Sciences, University of Tennessee Health Science Center, 881 Madison Ave, Memphis, TN 38163, USA.
Zhi K; Plough Center for Sterile Drug Delivery Solutions, University of Tennessee Health Science Center, 208 South Dudley Street, Memphis, TN 38163, USA.
Mukherji A; Department of Pharmaceutical Sciences, University of Tennessee Health Science Center, 881 Madison Ave, Memphis, TN 38163, USA.
Gerth K; Department of Pharmaceutical Sciences, University of Tennessee Health Science Center, 881 Madison Ave, Memphis, TN 38163, USA.
Pokaż więcej
Źródło :
Viruses [Viruses] 2020 Apr 26; Vol. 12 (5). Date of Electronic Publication: 2020 Apr 26.
Typ publikacji :
Journal Article; Review
Journal Info :
Publisher: MDPI Country of Publication: Switzerland NLM ID: 101509722 Publication Model: Electronic Cited Medium: Internet ISSN: 1999-4915 (Electronic) Linking ISSN: 19994915 NLM ISO Abbreviation: Viruses Subsets: MEDLINE
MeSH Terms :
Drug Repositioning*
Coronavirus Infections/*drug therapy
Extracellular Vesicles/*chemistry
HIV Protease Inhibitors/*administration & dosage
Pneumonia, Viral/*drug therapy
Betacoronavirus/genetics ; Betacoronavirus/metabolism ; Coronavirus Infections/epidemiology ; Coronavirus Infections/virology ; Drug Approval ; Drug Delivery Systems ; Humans ; Pandemics ; Pneumonia, Viral/epidemiology ; Pneumonia, Viral/virology
SCR Disease Name :
COVID-19
SCR Organism :
severe acute respiratory syndrome coronavirus 2
Czasopismo naukowe
Tytuł :
FDA orphan drug designations for lysosomal storage disorders - a cross-sectional analysis.
Autorzy :
Garbade SF; Division of Pediatric Neurology and Metabolic Medicine, Center for Pediatric and Adolescent Medicine, University Hospital Heidelberg, Heidelberg, Germany.
Zielonka M; Division of Pediatric Neurology and Metabolic Medicine, Center for Pediatric and Adolescent Medicine, University Hospital Heidelberg, Heidelberg, Germany.
Mechler K; Department of Child and Adolescent Psychiatry and Psychotherapy & Department of Addictive Behavior and Addiction Medicine, Medical Faculty Mannheim, Central Institute of Mental Health, University of Heidelberg, Mannheim, Germany.
Kölker S; Division of Pediatric Neurology and Metabolic Medicine, Center for Pediatric and Adolescent Medicine, University Hospital Heidelberg, Heidelberg, Germany.
Hoffmann GF; Division of Pediatric Neurology and Metabolic Medicine, Center for Pediatric and Adolescent Medicine, University Hospital Heidelberg, Heidelberg, Germany.
Staufner C; Division of Pediatric Neurology and Metabolic Medicine, Center for Pediatric and Adolescent Medicine, University Hospital Heidelberg, Heidelberg, Germany.
Mengel E; SphinCS GmbH, Science for LSD, Hochheim, Germany.
Ries M; Division of Pediatric Neurology and Metabolic Medicine, Center for Pediatric and Adolescent Medicine, University Hospital Heidelberg, Heidelberg, Germany.; Center for Rare Diseases, University Hospital Heidelberg, Heidelberg, Germany.; Center for Virtual Patients, Medical Faculty, University of Heidelberg, Heidelberg, Germany.
Pokaż więcej
Źródło :
PloS one [PLoS One] 2020 Apr 08; Vol. 15 (4), pp. e0230898. Date of Electronic Publication: 2020 Apr 08 (Print Publication: 2020).
Typ publikacji :
Journal Article
Journal Info :
Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS ONE Subsets: MEDLINE
MeSH Terms :
United States Food and Drug Administration*/legislation & jurisprudence
Lysosomal Storage Diseases/*drug therapy
Orphan Drug Production/*statistics & numerical data
Cross-Sectional Studies ; Databases, Pharmaceutical ; Drug Discovery ; Government Regulation ; Humans ; Orphan Drug Production/legislation & jurisprudence ; United States
Czasopismo naukowe
Tytuł :
Outcomes in diabetic macular edema switched directly or after a dexamethasone implant to a fluocinolone acetonide intravitreal implant following anti-VEGF treatment.
Autorzy :
Rehak M; Department of Ophthalmology, University Hospital Leipzig, Liebigstr. 10-14, 04103, Leipzig, Germany. .
Busch C; Department of Ophthalmology, University Hospital Leipzig, Liebigstr. 10-14, 04103, Leipzig, Germany.
Unterlauft JD; Department of Ophthalmology, University Hospital Leipzig, Liebigstr. 10-14, 04103, Leipzig, Germany.
Jochmann C; Department of Ophthalmology, University Hospital Leipzig, Liebigstr. 10-14, 04103, Leipzig, Germany.
Wiedemann P; Department of Ophthalmology, University Hospital Leipzig, Liebigstr. 10-14, 04103, Leipzig, Germany.
Pokaż więcej
Źródło :
Acta diabetologica [Acta Diabetol] 2020 Apr; Vol. 57 (4), pp. 469-478. Date of Electronic Publication: 2019 Nov 20.
Typ publikacji :
Journal Article
Journal Info :
Publisher: Springer Verlag Country of Publication: Germany NLM ID: 9200299 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-5233 (Electronic) Linking ISSN: 09405429 NLM ISO Abbreviation: Acta Diabetol Subsets: MEDLINE
MeSH Terms :
Drug Implants*
Bevacizumab/*therapeutic use
Dexamethasone/*administration & dosage
Diabetic Retinopathy/*drug therapy
Fluocinolone Acetonide/*administration & dosage
Macular Edema/*drug therapy
Aged ; Drug Administration Schedule ; Drug Substitution ; Female ; Humans ; Intraocular Pressure/drug effects ; Intravitreal Injections ; Male ; Middle Aged ; Retrospective Studies ; Treatment Outcome ; Vascular Endothelial Growth Factor A/antagonists & inhibitors ; Vascular Endothelial Growth Factor A/immunology ; Visual Acuity/drug effects
Czasopismo naukowe
Tytuł :
Treatment of urinary tract infections in the era of antimicrobial resistance and new antimicrobial agents.
Autorzy :
Bader MS; Staff Physician, Department of Medicine, Hamilton Health Sciences, Juravinski hospital and Cancer Centre , Hamilton, Ontario, Canada.
Loeb M; Departments of Pathology & Molecular Medicine and Clinical, Epidemiology & Biostatistics, McMaster University , Hamilton, Ontario, Canada.
Leto D; Department of Medicine and Pathology and Molecular Medicine, McMaster University, Hamilton Health Sciences, Juravinski Hospital and Cancer Centre , Hamilton, Ontario, Canada.
Brooks AA; Department of Pharmacy, Hamilton Health Sciences, Juravinski hospital and Cancer Centre , Hamilton, Ontario, Canada.
Pokaż więcej
Źródło :
Postgraduate medicine [Postgrad Med] 2020 Apr; Vol. 132 (3), pp. 234-250. Date of Electronic Publication: 2019 Oct 24.
Typ publikacji :
Journal Article; Review
Journal Info :
Publisher: Informa Healthcare Country of Publication: England NLM ID: 0401147 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1941-9260 (Electronic) Linking ISSN: 00325481 NLM ISO Abbreviation: Postgrad Med Subsets: Core Clinical (AIM); MEDLINE
MeSH Terms :
Drug Resistance, Bacterial*
Anti-Bacterial Agents/*therapeutic use
Gram-Negative Bacterial Infections/*drug therapy
Urinary Tract Infections/*drug therapy
Anti-Bacterial Agents/administration & dosage ; Anti-Bacterial Agents/adverse effects ; Drug Combinations ; Drug Therapy, Combination ; Humans ; Pyelonephritis/drug therapy
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies